Search Bar & Filters
Found 89 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and initial effects of T3011, given directly into tumors, alone and combined with the intravenous drug pembrolizumab. This Phase 12a open-label study focuses on adults with advanced or metastatic solid tumors, including melanoma, head and neck squamous cell carcinoma HNSCC, sarcoma, cutaneous squamous cell carcinoma cSCC, and non-small cell lung cancer NSCLC. The study aims to find safe dose levels and assess how well these treatments are tolerated and work in these cancer types. The study involves several groups Phase 1 tests increasing doses of T3011 alone to determine a recommended dose. Phase 2a Part 1 evaluates T3011 alone in participants with melanoma, HNSCC, sarcoma, and cSCC. Phase 2a Part 2 studies T3011 with pembrolizumab in NSCLC patients. A rollover arm allows participants whose cancer progresses on T3011 alone to receive the combination treatment. T3011 is given as an intratumoral injection every two weeks, and pembrolizumab is given intravenously every three weeks when combined. Participants will have tumor biopsies, imaging, and laboratory tests to monitor safety, drug levels, and cancer response. Researchers will track side effects and measure outcomes like tumor response and survival for up to two years after the first dose. Safety and tolerability are closely followed throughout, with additional monitoring for immune responses and drug presence in bodily fluids. Participants may be followed for up to one year after their last treatment dose to assess overall survival and long-term effects.
Actively Recruiting
Researchers are evaluating the combination of BNT324, a B7-H3 antibody-drug conjugate, with BNT327, a bispecific antibody targeting PD-L1 and VEGF, in adults with advanced or metastatic small cell lung cancer SCLC and non-small cell lung cancer NSCLC. This two-part Phase IbII trial aims to find safe dose levels, optimize dosing, and assess preliminary efficacy and safety in various lung cancer patient groups. Participants in Part 1 receive escalating doses of BNT324 with BNT327 to determine recommended dose levels. Part 2 compares these dose levels in randomized cohorts of treatment-naive NSCLC and relapsed SCLC patients, with additional cohorts receiving the optimal dose to further evaluate efficacy and safety. Treatments are given via intravenous infusion, and dosing is adjusted based on safety and response data. Throughout the study, participants undergo screening, treatment, safety follow-up, and long-term survival monitoring. Researchers assess dose-limiting toxicities, adverse events, objective response rates, disease control, progression-free survival, and overall survival. Treatment effects are evaluated up to 87 months, with close monitoring for side effects and treatment tolerability during and after therapy.
Actively Recruiting
This trial is designed for adults diagnosed with metastatic pancreatic ductal adenocarcinoma PDAC who have not yet received systemic treatment for their advanced cancer and have a good performance status. The study evaluates pumitamig, an investigational drug, in combination with chemotherapy to assess its safety and effectiveness. This phase II trial plans to explore different chemotherapy regimens combined with pumitamig to understand their impact on the disease.
Actively Recruiting
Researchers are evaluating the effects of NB-4746 compared with placebo in adults with amyotrophic lateral sclerosis ALS. This trial aims to understand the safety, side effects, how NB-4746 moves through the body, and changes in a blood marker called neurofilament light NfL, which indicates nerve cell damage. The study is divided into two parts and includes an optional open-label extension. In Part A, participants are randomly assigned to receive either a low dose of NB-4746, a high dose of NB-4746, or placebo capsules taken twice daily for about one month. In Part B, participants are again randomized to receive NB-4746 at a dose determined based on Part A results or placebo capsules twice daily for about twelve weeks. After completing Part A or B, participants may opt to continue treatment in an open-label extension lasting up to one year. Participants will be monitored throughout the trial with regular health checks focusing on ALS symptoms and overall wellbeing. Researchers will track adverse events, measure blood levels of NB-4746, and assess changes in neurofilament light to evaluate nerve damage. Safety and tolerability will be evaluated from enrollment through the treatment periods, with ongoing monitoring during the extension phase.
Actively Recruiting
Researchers are evaluating ONM-501, a drug given as intratumoral injections, alone and in combination with cemiplimab, an immune checkpoint inhibitor, in patients with advanced solid tumors and lymphomas. This phase 1 study aims to find the maximum tolerated dose, minimum effective dose, and recommended dose for expansion of ONM-501. The study includes patients with various advanced cancers who have no alternative standard therapies available. The trial has three parts monotherapy dose escalation, combination therapy dose finding, and combination therapy dose expansion. ONM-501 is given once per week for three weeks followed by three weeks off, in 21-day cycles. Cemiplimab is given intravenously every three weeks during the combination phases. Dose escalation uses special methods to gradually increase doses, and after doses are established, patients will enroll in expansion cohorts for specific tumor types. Participants will have regular assessments including monitoring for side effects, blood tests to measure drug levels, and evaluation of tumor response over up to 24 months. Researchers will track treatment-emergent adverse events, dose-limiting toxicities, and serious adverse events. Outcomes such as objective response rate, duration of response, progression-free survival, and overall survival will also be recorded. The study involves close safety monitoring and follow-up throughout the treatment and observation periods.
Actively Recruiting
Researchers are evaluating ZE94-0605, an oral selective cyclin-dependent kinase 2 CDK2 inhibitor, in adults with advanced, unresectable, or metastatic solid tumors that have not responded to or are intolerant of existing therapies. This first-in-human, open-label Phase 1 study consists of two parts Phase 1a to find the highest safe dose and biologically effective dose through sequential dose escalation, and Phase 1b to randomize participants with specific molecular features such as CCNE1 amplification to determine the recommended Phase 2 dose. ZE94-0605 is given orally once daily in a fasted state in continuous 28-day cycles. Phase 1a explores doses from 50 mg optional up to 650 mg or higher if needed, while Phase 1b randomizes about 30 participants to receive either the maximum tolerated dose or one dose level below it. Treatment continues until disease progression, unacceptable side effects, withdrawal, or completion of 26 cycles. Participants will undergo regular assessments including response evaluations before dosing on several cycle days, detailed pharmacokinetic and biomarker testing during early cycles, and circulating tumor DNA analysis at multiple timepoints. Researchers will monitor safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity. The study duration may extend up to approximately 24 months with ongoing monitoring and follow-up.
Actively Recruiting
Researchers are evaluating the long-term safety, tolerability, and lasting effects of ALKS 2680 tablets in adults with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia. This study involves participants who have completed earlier ALKS 2680 parent studies and aims to continue monitoring treatment impact over an extended period. Participants receive oral ALKS 2680 tablets once daily at doses ranging from 4 mg to 18 mg. The study follows a non-randomized, open-label design, and includes three groups based on the specific condition Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. The treatment duration extends up to 248 weeks, allowing long-term observation of the medications effects. During the study, participants undergo regular assessments including monitoring for adverse events, changes in sleep latency using the Maintenance of Wakefulness Test, sleepiness severity via the Epworth Sleepiness Scale, weekly cataplexy rate, and idiopathic hypersomnia severity. Safety and treatment effects are tracked throughout the study period, which may last up to nearly five years, ensuring ongoing evaluation of participant health and treatment durability.
Actively Recruiting
Researchers are studying the safety, tolerability, how the body processes the drug, and the best dose for a new oral medicine called D3S-002 in adults with advanced solid tumors that have specific mutations in the MAPK pathway. This is a first-in-human trial involving adults with cancers that have progressed despite prior treatments. The study aims to find the recommended dose for future studies and to evaluate the drug as a single treatment or combined with another drug, D3S-001. The study has two main parts Part 1 involves gradually increasing doses of D3S-002 given orally to find a safe dose, while Part 2 includes dose escalation and expansion phases where D3S-002 is given with D3S-001, both administered by mouth. Treatment cycles last 21 days, and participants receive the study drugs daily during these cycles. The study is open-label, meaning both doctors and participants know which treatment is given. Participants will be closely monitored for side effects, how the drugs behave in the body, and tumor response using established criteria. Safety is tracked from the first dose until 30 days after stopping treatment, and dosing effects are followed for up to 24 months. Genetic testing on tumor tissue or blood samples is part of the study, along with regular assessments of organ function, performance status, and disease progression. The study continues until disease progression or other reasons to stop treatment.
Actively Recruiting
Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.
Actively Recruiting
Randomized Study Comparing Partial Versus Whole Breast Irradiation in Women with Early Breast Cancer
Researchers are evaluating radiation treatments for women with small, node-negative invasive breast cancer measuring 3 cm or less. This trial compares partial breast irradiation PBI to whole breast irradiation WBI, both given once daily over about one week after breast-conserving surgery. The main goal is to see if PBI is not worse than WBI for preventing local cancer recurrence and if it improves cosmetic outcomes, as judged by patients, three years after treatment. Participants are randomly assigned to receive either PBI or WBI. Both groups receive a total radiation dose of 26 Gy split into five daily treatments over 5 to 7 days, with a possible extension to 8 days due to scheduling. The WBI targets the entire breast, while PBI focuses radiation on the tumor bed plus a margin of normal tissue. Patients are not informed which treatment they receive to avoid bias in assessing cosmetic results. Key factors such as tumor size, estrogen receptor status, and treatment center are used for group assignment. During the study, participants will be monitored annually for five years to assess local recurrence, distant disease-free survival, overall survival, and radiation side effects. Cosmetic outcomes will be evaluated by both patients and clinical staff at 3 and 5 years. Quality of life will also be measured at multiple time points. The study lasts several years, with primary outcomes assessed at three years and continued follow-up through at least five years post-treatment.
1-10 of 89
1